Sort   by:  
 Page size 
UnknownNecrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection.
Not available
S-EPMC7390563 | biostudies-literature
UnknownOutcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
Not available
S-EPMC8847487 | biostudies-literature
UnknownTreatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.
Not available
S-EPMC6292452 | biostudies-literature
UnknownDalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials.
Not available
S-EPMC10249272 | biostudies-literature
UnknownSafety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Not available
S-EPMC7955009 | biostudies-literature
UnknownDalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
Not available
S-EPMC6326511 | biostudies-literature
UnknownDalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Not available
S-EPMC9109297 | biostudies-literature
UnknownDevelopment of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial.
Not available
S-EPMC9168013 | biostudies-literature
UnknownPhage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial.
Not available
S-EPMC12216271 | biostudies-literature
UnknownDalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.
Not available
S-EPMC12351474 | biostudies-literature
Sort   by:  
 Page size